

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 March 2001 (01.03.2001)

PCT

(10) International Publication Number
WO 01/14421 A1

(51) International Patent Classification: **C07K 14/315,**
C12N 15/31, C07K 16/12, A61K 39/09, 39/40

(21) International Application Number: **PCT/US00/23417**

(22) International Filing Date: **25 August 2000 (25.08.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data: **60/150,750** **25 August 1999 (25.08.1999)** **US**

(71) Applicant: **MEDIMMUNE, INC. [US/US]; 35 West**
Watkins Mill Road, Gaithersburg, MD 20878 (US).

(72) Inventors: **KOENIG, Scott; 10901 Ralston Road,**
Rockville, MD 20852 (US). HEINRICHS, Jon; 9 Peach

Leaf Court, North Potomac, MD 20878 (US). **JOHNSON,**
Leslie, Sydnor; 20147 Laurel Hill Way, Germantown, MD
20874 (US). ADAMOU, John, E.; 20822 Shamrock Glen
Circle, Germantown, MD 20874 (US).

(74) Agents: **GRANT, Alan, J. et al.; Carella, Byrne, Bain,**
Gillfillan, Cecchi, Stewart & Olstein, 6 Becker Farm Road,
Roseland, NJ 07068 (US).

(81) Designated States (national): **AL, AM, AT, AU, AZ, BA,**
BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM,
EE, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IN, IS, JP,
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ,
VN, YU, ZA, ZW.

(84) Designated States (regional): **ARIPO patent (GH, GM,**
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European

[Continued on next page]

(54) Title: **HOMOLOGS OF A PNEUMOCOCCAL PROTEIN AND FRAGMENTS FOR VACCINES**

S. aureus 6390
S. pyogenes M1
S. pyogenes M6
S. pneumoniae

<i>S. aureus</i> 6390		<i>S. pyogenes</i> M1		<i>S. pyogenes</i> M6		<i>S. pneumoniae</i>	
B	P	B	P	B	P	B	P

(57) Abstract: The invention is directed to isolated polypeptides bearing sequence homology to the Sp36 protein found in pneumococcal organisms, such as *Streptococcus pneumoniae*. Polynucleotides encoding such polypeptides are also disclosed. The invention also relates to antibodies specific for the disclosed polypeptides and to uses of such antibodies in the treatment of diseases caused by staphylococci as well as group A and B streptococci. In addition, the invention relates to the use of the disclosed polypeptides in compositions and as vaccines and for prophylactic uses such as in vaccination of animals, especially humans, against a wide variety of streptococcal, staphylococcal and other diseases.

WO 01/14421 A1



patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

— Before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments.

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

Published:

— With international search report.

HOMOLOGS OF A PNEUMOCOCCAL PROTEIN AND FRAGMENTS FOR VACCINES

5

This application claims the priority of U.S. Provisional Application 60/150,750, filed August 25, 1999, the disclosure of which is hereby incorporated by reference in its entirety.

10

FIELD OF THE INVENTION

This invention relates generally to the field of bacterial antigens and their use, for example, as immunogenic agents in humans and animals to stimulate an immune response. More specifically, it relates to the vaccination of mammalian species, especially humans, with one or more polypeptides derived from gram positive bacteria and which show sequence homology with an immunogenic polypeptide obtained from *Streptococcus pneumoniae*.

20

BACKGROUND OF THE INVENTION

Polypeptides derived from gram positive bacteria are useful for stimulating production of antibodies that protect the vaccine recipient against infection by a wide range of serotypes of pathogenic gram positive bacteria, including *S. pneumoniae*. Further, the invention relates to antibodies against such polypeptides useful in diagnosis and passive immune therapy with respect to diagnosing and treating such pneumococcal infections.

30

The genus *Streptococcus* contains a variety of species responsible for causing disease in mammals, including humans, while also encompassing species that constitute normal flora in humans and other mammals. Among the bacterial species implicated in the etiology of diseases in humans are *S. pyogenes* (part of the group A streptococcal bacteria, herein designated "GAS" for "group A streptococci"), *S. pneumoniae* (referred to as "pneumococcus") and *S. agalactiae* (the group B streptococci or "GBS"). The group A streptococci cause serious diseases such as necrotizing fasciitis, scarlet fever and sepsis, as well as less virulent diseases such as impetigo and pharyngitis. The pneumococci are the most common cause of community-acquired pneumonia and are also responsible for more than half of all cases of otitis media in children. The pneumococci are also the second most common pathogen associated with bacterial meningitis. The group B streptococci are the most prevalent pathogen associated with illness and death among newborns in the United States.

Currently, there are no vaccines available for the prevention of diseases caused by the group A and group B streptococci and presently available pneumococcal vaccines are not effective in children under 2 years of age or in the elderly due to the poor immunogenicity of the capsular carbohydrates that compose the current vaccine. It would therefore be highly advantageous to produce a vaccine that would prevent infection by these classes of pathogen, especially in the age groups mentioned.

In addition to the pathogens just described, some bacteria of the genus *Staphylococcus* are also of clinical importance. In fact, two of these are among the leading causes of nosocomial infections (infections acquired while in the hospital). Both *Staphylococcus aureus* and *Staphylococcus epidermidis* readily colonize the skin of healthy individuals and can cause acute disease in patients following immunosuppression or traumatic injury. Infections caused by these species include bacteremia, endocarditis,

osteomyelitis, wound infections and infections associated with indwelling catheters.

5 *Streptococcus pneumoniae* is a gram positive bacterium that is a major causative agent in invasive infections in animals and humans, such as the aforementioned sepsis, meningitis, and otitis media, as well as lobar pneumonia (Tuomanen, *et al. New England J. of Medicine* 322:1280-1284 (1995)). As part of the infection process, pneumococci readily bind to non-inflamed human epithelial cells of the upper and lower respiratory tract by
10 binding to eukaryotic carbohydrates in a lectin-like manner (Cundell *et al., Micro. Path.* 17:361-374 (1994)). Conversion to invasive pneumococcal infections for bound bacteria may involve the local generation of inflammatory factors which may activate the epithelial cells to change the number and type of receptors on their surface (Cundell, *et al., Nature*,
15 377:435-438 (1995)). Apparently, one such receptor, platelet activating factor (PAF) is engaged by the pneumococcal bacteria and within a very short period of time (minutes) from the appearance of PAF, pneumococci exhibit strongly enhanced adherence and invasion of tissue. Certain soluble receptor analogs have been shown to prevent the progression of
20 pneumococcal infections (Idanpaan-Heikkila *et al., J. Inf. Dis.*, 176:704-712 (1997)). A number of other proteins have been suggested as being involved in the pathogenicity of *S. pneumoniae*.

Streptococcus pneumoniae itself has been shown to contain a gene
25 which encodes a protein designated herein as Sp36. This protein has a predicted molecular mass of 91,538 Da and contains 5 histidine triad motifs (proposed to be involved in metal binding). The gene encoding this protein appears to be present the 23 serotypes comprising the current commercially available pneumococcal-capsular vaccine. Immunization of mice with this
30 protein, in the presence of Freund's adjuvant, stimulates an immune

response which protects these mice from an intraperitoneal challenge with a dose of virulent pneumococci that would normally kill the mice.

5 For the reasons already stated above, there not only remains a need for identifying polypeptides having epitopes in common from various strains of *S. pneumoniae* but also from a broader spectrum of gram positive bacteria in order to utilize such polypeptides as vaccines to provide protection against a wide variety of infectious organisms.

10 BRIEF SUMMARY OF THE INVENTION

In accordance with the present invention, there is provided vaccines that include polypeptides obtained from gram positive bacteria other than *S. pneumoniae*, as well as variants of said polypeptides and active fragments
15 of such polypeptides.

The present invention is also directed to novel genes, and the polypeptides encoded thereby, derived from gram positive bacteria other than *S. pneumoniae*, and which bear sequence homology to the Sp36 gene
20 already described. Such gram positive bacteria include the group A and B streptococci, as described herein, as well as species of the genus *Staphylococcus*, especially *S. aureus*.

In a particular embodiment, the present invention is directed to
25 specific gene sequences, and proteins encoded thereby, derived from the group A and group B streptococci, and to the use of such expressed polypeptides and proteins as the basis for pharmaceutical compositions useful as vaccines and as a means for enabling isolation of antibodies with therapeutic and/or prophylactic activity (such as would be useful in
30 preparing products like CytoGam).

In a further embodiment, the present invention also relates to the preparation and use of fragments of the novel polypeptides disclosed herein, such fragments being immunogenic in nature and being useful in the preparation of vaccines against diseases caused by the pathogens from which such polypeptides, and fragments thereof, are derived.

10

BRIEF DESCRIPTION OF DRAWINGS

Figures 1 shows the results of a Southern blot of genomic DNA from *S. aureus*, *S. pyogenes*, and pneumococcus. The DNA was digested with restriction nucleases *Bam*HI or *Pvu*II, and after electrophoresis and transfer to a nylon membrane, was probed with a labeled DNA fragment encompassing the pneumococcal gene encoding Sp36. The hybridization and washes were carried out under low stringency conditions. The results show hybridization by the labeled probe to a *S. aureus* fragment in both the *Bam*HI and *Pvu*II lanes and to two fragments in the *Pvu*II digests of two strains of *S. pyogenes*.

Figures 2 shows an alignment between the Sp36 amino acid sequence from *S. pneumoniae* strain N4 and the homologous sequences from *S. pyogenes* and *S. agalactiae*. Amino acids identical to those of the polypeptide from *S. pneumoniae* are boxed.

Figure 3 shows the results of a Southern blot of genomic DNA from *S. pyogenes*, *S. agalactiae*, and *S. pneumoniae* probed with DNA encoding the full length Sp36 homolog from *S. pyogenes*. The

hybridization was carried out under low stringency conditions. These results demonstrate that the *S. pyogenes* Sp36 homolog, used as a probe, is capable of detecting a homologous gene in *S. agalactiae* and pneumococcus.

5

Figure 4 shows the results of a western blot using rabbit polyclonal antiserum generated against recombinant Sp36 protein cloned from *S. pneumoniae* strain Norway 4. The results demonstrate that this antiserum not only reacts with the protein against which it was raised (here, Sp36),
10 as well as to a protein of similar size in a lysate of a serotype 6B strain of pneumococcus, but also reacts with a recombinant protein encoded by the Sp36 homolog gene of group B streptococci.

Figure 5 shows the amino acid sequence for the GAS36 homologs
15 with the histidine triad regions underlined (Fig. 5(a) and (b)) and the sequence for a GBS36 homolog (Fig. 5(c)) with its histidine triad regions underlined.

20

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to novel polynucleotides and polypeptides derived from species of gram positive bacteria, especially
25 group A and B streptococci, and including the genus *Staphylococcus*, most especially *S. pyogenes* (GAS), *S. agalactiae* (GBS), and *S. aureus*, respectively.

Further, the present invention is directed to polynucleotides derived
30 from gram positive bacteria and which are at least partially homologous to

the polynucleotides making up the gene coding for the previously disclosed Sp36 gene of *S. pneumoniae* (U.S. Application Serial No. 60/113,048).

5 The present invention is also directed to polynucleotides, and immunologically active fragments, segments, or portions, thereof, which polypeptides are encoded by the polynucleotides disclosed herein.

The present invention also relates to such polynucleotides and polypeptides in enriched, preferably isolated, or even purified, form.

10 In accordance with the present invention, the term "DNA segment" refers to a DNA polymer, in the form of a separate fragment or as a component of a larger DNA construct, which has been derived from DNA isolated at least once in substantially pure form, i.e., free of
15 contaminating endogenous materials and in a quantity or concentration enabling identification, manipulation, and recovery of the segment and its component nucleotide sequences by standard biochemical methods, for example, using a cloning vector. Such segments are provided in the form of an open reading frame uninterrupted by internal nontranslated
20 sequences, or introns, which are typically present in eukaryotic genes. Sequences of non-translated DNA may be present downstream from the open reading frame, where they do not interfere with manipulation or expression of the coding regions.

25 The nucleic acids and polypeptide expression products disclosed according to the present invention, as well as expression vectors containing such nucleic acids and/or such polypeptides, may be in "enriched form." As used herein, the term "enriched" means that the concentration of the material is at least about 2, 5, 10, 100, or 1000
30 times its natural concentration (for example), advantageously 0.01%, by weight, preferably at least about 0.1% by weight. Enriched preparations

of about 0.5%, 1%, 5%, 10%, and 20% by weight are also contemplated. The sequences, constructs, vectors, clones, and other materials comprising the present invention can advantageously be in enriched or isolated form.

5

"Isolated" in the context of the present invention with respect to polypeptides (or polynucleotides) means that the material is removed from its original environment (*e.g.*, the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living organism is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the co-existing materials in the natural system, is isolated. Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment. The polypeptides and polynucleotides of the present invention are preferably provided in an isolated form, and most preferably are purified to homogeneity.

The polynucleotides, and recombinant or immunogenic polypeptides, disclosed in accordance with the present invention may also be in "purified" form. The term "purified" does not require absolute purity; rather, it is intended as a relative definition, and can include preparations that are highly purified or preparations that are only partially purified, as those terms are understood by those of skill in the relevant art. For example, individual clones isolated from a cDNA library have been conventionally purified to electrophoretic homogeneity. Purification of starting material or natural material to at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated. Furthermore, claimed polypeptides having a purity of preferably 0.001%, or at least 0.01% or 0.1%; and even 1% by weight or greater is expressly contemplated.

The term "coding region" refers to that portion of a gene which either naturally or normally codes for the expression product of that gene in its natural genomic environment, i.e., the region coding *in vivo* for the native expression product of the gene. The coding region can be from a normal, mutated or altered gene, or can even be from a DNA sequence, or gene, wholly synthesized in the laboratory using methods well known to those of skill in the art of DNA synthesis.

In accordance with the present invention, the term "nucleotide sequence" refers to a heteropolymer of deoxyribonucleotides. Generally, DNA segments encoding the proteins provided by this invention are assembled from cDNA fragments and short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic gene which is capable of being expressed in a recombinant transcriptional unit comprising regulatory elements derived from a microbial or viral operon.

The term "expression product" means that polypeptide or protein that is the natural translation product of the gene and any nucleic acid sequence coding equivalents resulting from genetic code degeneracy and thus coding for the same amino acid(s).

The term "fragment," when referring to a coding sequence, means a portion of DNA comprising less than the complete coding region whose expression product retains essentially the same biological function or activity as the expression product of the complete coding region.

The term "primer" means a short nucleic acid sequence that is paired with one strand of DNA and provides a free 3'OH end at which a DNA polymerase starts synthesis of a deoxyribonucleotide chain.

The term "promoter" means a region of DNA involved in binding of RNA polymerase to initiate transcription.

5 The term "open reading frame (ORF)" means a series of triplets coding for amino acids without any termination codons and is a sequence (potentially) translatable into protein.

10 As used herein, reference to a DNA sequence includes both single stranded and double stranded DNA. Thus, the specific sequence, unless the context indicates otherwise, refers to the single strand DNA of such sequence, the duplex of such sequence with its complement (double stranded DNA) and the complement of such sequence.

15 In accordance with the present invention, the term "percent identity" or "percent identical," when referring to a sequence, means that a sequence is compared to a claimed or described sequence after alignment of the sequence to be compared (the "Compared Sequence") with the described or claimed sequence (the "Reference Sequence"). The Percent Identity is then determined according to the following formula:

20

$$\text{Percent Identity} = 100 [1 - (C/R)]$$

25 wherein C is the number of differences between the Reference Sequence and the Compared Sequence over the length of alignment between the Reference Sequence and the Compared Sequence wherein (i) each base or amino acid in the Reference Sequence that does not have a corresponding aligned base or amino acid in the Compared Sequence and (ii) each gap in the Reference Sequence and (iii) each aligned base or amino acid in the
30 Reference Sequence that is different from an aligned base or amino acid in the Compared Sequence, constitutes a difference; and R is the number of

bases or amino acids in the Reference Sequence over the length of the alignment with the Compared Sequence with any gap created in the Reference Sequence also being counted as a base or amino acid.

5 If an alignment exists between the Compared Sequence and the Reference Sequence for which the percent identity as calculated above is about equal to or greater than a specified minimum Percent Identity then the Compared Sequence has the specified minimum percent identity to the Reference Sequence even though alignments may exist in which the
10 hereinabove calculated Percent Identity is less than the specified Percent Identity.

 Thus, the present invention is directed to novel, isolated polypeptides comprising an amino acid sequence at least 75% identical to a sequence in
15 SEQ ID NO: 2, 4 or 6, preferably polypeptides at least 90% identical thereto, more preferably 95% identical to the sequence of SEQ ID NO: 2 or 4, and most preferably having the sequence of either SEQ ID NO: 2 or 4.

 The isolated polypeptides of the present invention may be found in a
20 wide variety of microorganisms, but will commonly be found in an organism selected from the group consisting of group A streptococci, group B streptococci, and *Staphylococcus aureus*, and wherein the group A streptococcal organism is *Streptococcus pyogenes* and the group B streptococcal organism is *Streptococcus agalactiae*. Also, polypeptides of
25 the invention include, but are in no way limited to, isolated polypeptides having a sequence at least 25% identical to the amino acid sequence of the Sp36 protein of *Streptococcus pneumoniae*.

 The present invention further relates to immunogenically active
30 fragments of the isolated polypeptides disclosed herein.

The terms "fragment," "derivative" and "analog" when referring to the polypeptides disclosed herein means a polypeptide which retains essentially the same biological function or activity as such polypeptide. Thus, an analog includes a proprotein, or preprotein, which can be
5 activated by cleavage of the proprotein portion to produce an active mature polypeptide. Such fragments, derivatives and analogs must have sufficient similarity to the polypeptide of SEQ ID NO:2, 4 or 6 so that immunogenic activity of the native polypeptide is retained.

The polypeptide of the present invention may be a recombinant
10 polypeptide, a natural polypeptide or a synthetic polypeptide, preferably a recombinant polypeptide.

The fragment, derivative or analog of the polypeptide of SEQ ID NO:2, 4, or 6 may be (i) one in which one or more of the amino acid
15 residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid residues includes a substituent group, or (iii) one in which the mature polypeptide is fused with
20 another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or (iv) one in which the additional amino acids are fused to the mature polypeptide, such as a leader or secretory sequence or a sequence which is employed for purification of the mature polypeptide or a proprotein sequence. Such fragments,
25 derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein.

As known in the art "similarity" between two polypeptides is determined by comparing the amino acid sequence and its conserved amino
30 acid substitutes of one polypeptide to the sequence of a second polypeptide.

Fragments or portions of the polypeptides of the present invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, the fragments may be employed as intermediates for producing the full-length polypeptides. Fragments or portions of the polynucleotides of the present invention may be used to synthesize full-length polynucleotides of the present invention.

As used herein with reference to polypeptides, the terms "portion," "segment," and "fragment," refer also to a continuous sequence of residues, such as amino acid residues, which sequence forms a subset of a larger sequence. For example, if a polypeptide were subjected to treatment with any of the common endopeptidases, such as trypsin, chymotrypsin, or papain, the oligopeptides resulting from such treatment would represent portions, segments or fragments of the starting polypeptide.

The present invention is also directed to isolated polynucleotides whose sequences contain coding regions encoding the polypeptides of the present invention, preferably the polypeptides of SEQ ID NO: 2, 4, and 6 and most preferably will be the isolated polynucleotides comprising the sequences of SEQ ID NOS: 1, 3, and 5.

The present invention is also directed to fragments or portions of such sequences which contain at least 15 bases, preferably at least 30 bases, more preferably at least 50 bases and most preferably at least 80 bases, and to those sequences which are at least 60%, preferably at least 80%, and most preferably at least 95%, especially 98%, identical thereto, and to DNA (or RNA) sequences encoding the same polypeptide as the sequences of SEQ ID NOS: 2, 4, and 6 including fragments and portions thereof and, when derived from natural sources, includes alleles thereof.

Yet another aspect of the present invention is directed to an isolated DNA (or RNA) sequence or molecule comprising at least the coding region of a bacterial gene (or a DNA sequence encoding the same polypeptide as such coding region), in particular an expressed bacterial gene, which bacterial gene comprises a DNA sequence homologous with, or contributing to, the sequence depicted in SEQ ID NOS: 1, 3, and 5 or one at least 60%, preferably at least 80%, and most preferably at least 95%, especially 98%, identical thereto, including 100% identity, as well as fragments or portions of the coding region which encode a polypeptide having a similar function to the polypeptide encoded by said coding region. Thus, the isolated DNA (or RNA) sequence may include only the coding region of the expressed gene (or fragment or portion thereof as hereinabove indicated) or may further include all or a portion of the non-coding DNA (or RNA) of the expressed bacterial gene.

In general, sequences homologous with and contributing to the sequences of SEQ ID NOS: 1, 3, and 5 (or one at least 60%, preferably at least 80%, and most preferably at least 95% identical or homologous thereto) are from the coding region of a bacterial gene.

The polynucleotides according to the present invention may also occur in the form of mixtures of polynucleotides hybridizable to some extent with the gene sequences containing any of the nucleotide sequences of SEQ ID NOS: 1, 3, and 5, including any and all fragments thereof, and which polynucleotide mixtures may be composed of any number of such polynucleotides, or fragments thereof, including mixtures having at least 10, perhaps at least 30 such sequences, or fragments thereof.

Fragments of the full length polynucleotide of the present invention may be used as hybridization probes for a DNA library to isolate the full

length DNA and to isolate other DNAs which have a high sequence similarity to the gene or similar biological activity. Probes of this type preferably have at least 15 bases, may have at least 30 bases and even 50 or more bases. The probe may also be used to identify a DNA clone
5 corresponding to a full length transcript and a genomic clone or clones that contain the complete gene including regulatory and promotor regions. An example of a screen comprises isolating the coding region of the gene by using the known DNA sequence to synthesize an oligonucleotide probe. Labeled oligonucleotides having a sequence complementary to that of the
10 gene of the present invention are used to screen a library of DNA or mRNA to determine which members of the library the probe hybridizes to.

The present invention is also directed to vectors comprising the polynucleotides disclosed herein, as well as to genetically engineered cells
15 comprising such vectors and/or polynucleotides. Thus, the present invention also relates to vectors which include polynucleotides of the present invention, host cells which are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques.

20 Host cells are genetically engineered (transduced or transformed or transfected) with the vectors of this invention which may be, for example, a cloning vector or an expression vector. The vector may be, for example, in the form of a plasmid, a viral particle, a phage, etc. The engineered host
25 cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the genes of the present invention. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

30

The polynucleotides of the present invention may be employed for producing polypeptides by recombinant techniques. Thus, for example, the polynucleotide may be included in any one of a variety of expression vectors for expressing a polypeptide. Such vectors include chromosomal, nonchromosomal and synthetic DNA sequences, e.g., derivatives of SV40; 5 bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, and pseudorabies. However, any other vector may be used as long as it is replicable and viable in the host.

10 The appropriate DNA sequence may be inserted into the vector by a variety of procedures. In general, the DNA sequence is inserted into an appropriate restriction endonuclease site(s) by procedures known in the art. Such procedures and others are deemed to be within the scope of those 15 skilled in the art.

The DNA sequence in the expression vector is operatively linked to an appropriate expression control sequence(s) (promoter) to direct mRNA synthesis. As representative examples of such promoters, there may be 20 mentioned: LTR or SV40 promoter, the E. coli. lac or trp, the phage lambda P_L promoter and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses. The expression vector also contains a ribosome binding site for translation initiation and a transcription terminator. The vector may also include appropriate sequences for 25 amplifying expression.

In addition, the expression vectors preferably contain one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells such as dihydrofolate reductase or neomycin 30 resistance for eukaryotic cell culture, or such as tetracycline or ampicillin resistance in E. coli.

The vector containing the appropriate DNA sequence as hereinabove described, as well as an appropriate promoter or control sequence, may be employed to transform an appropriate host to permit the host to express the
5 protein.

As representative examples of appropriate hosts, there may be mentioned: bacterial cells, such as E. coli, Streptomyces, Salmonella typhimurium; fungal cells, such as yeast; insect cells such as Drosophila S2
10 and Spodoptera Sf9; animal cells such as CHO, COS or Bowes melanoma; adenoviruses; plant cells, etc. The selection of an appropriate host is deemed to be within the scope of those skilled in the art from the teachings herein.

15 More particularly, the present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above. The constructs comprise a vector, such as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct
20 further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available. The following vectors are provided by way of example; Bacterial:
25 pQE70, pQE60, pQE-9 (Qiagen), pBS, pD10, phagescript, phiX174, pBluescript SK, pBSKS, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene); pTRC99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia); Eukaryotic:
pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia). However, any other plasmid or vector may be
used as long as they are replicable and viable in the host.

30

Promoter regions can be selected from any desired gene using CAT (chloramphenicol transferase) vectors or other vectors with selectable markers. Two appropriate vectors are pKK232-8 and pCM7. Particular named bacterial promoters include lacI, lacZ, T3, T7, gpt, lambda P_R, P_L and trp. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art.

10 In a further embodiment, the present invention relates to host cells containing the above-described constructs. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by
15 calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Davis, L., Dibner, M., Battey, I., Basic Methods in Molecular Biology, (1986)).

The constructs in host cells can be used in a conventional manner to
20 produce the gene product encoded by the recombinant sequence. Alternatively, the polypeptides of the invention can be synthetically produced by conventional peptide synthesizers.

Mature proteins can be expressed in mammalian cells, yeast,
25 bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention. Appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrook, et al., Molecular Cloning: A
30 Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), the disclosure of which is hereby incorporated by reference.

Transcription of the DNA encoding the polypeptides of the present invention by higher eukaryotes is increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp that act on a promoter to increase its transcription. Examples include the SV40 enhancer on the late side of the replication origin bp 100 to 270, a cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers.

10

Generally, recombinant expression vectors will include origins of replication and selectable markers permitting transformation of the host cell, e.g., the ampicillin resistance gene of E. coli and S. cerevisiae Trp1 gene, and a promoter derived from a highly-expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK), α -factor, acid phosphatase, or heat shock proteins, among others. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably, a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium. Optionally, the heterologous sequence can encode a fusion protein including an N-terminal identification peptide imparting desired characteristics, e.g., stabilization or simplified purification of expressed recombinant product.

25

Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter. The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector and to, if desirable, provide amplification within

30

the host. Suitable prokaryotic hosts for transformation include E. coli, Bacillus subtilis, Salmonella typhimurium and various species within the genera Pseudomonas, Streptomyces, and Staphylococcus, although others may also be employed as a matter of choice.

5

As a representative but nonlimiting example, useful expression vectors for bacterial use can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids comprising genetic elements of the well known cloning vector pBR322 (ATCC 37017).

10

Such commercial vectors include, for example, pKK223-3 (Pharmacia Fine Chemicals, Uppsala, Sweden) and GEM1 (Promega Biotec, Madison, WI, USA). These pBR322 "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed.

15

Following transformation of a suitable host strain and growth of the host strain to an appropriate cell density, the selected promoter is induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period.

20

Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.

25

Microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents, such methods are well known to those skilled in the art.

30

Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by

Gluzman, Cell, 23:175 (1981), and other cell lines capable of expressing a compatible vector, for example, the C127, 3T3, CHO, HeLa and BHK cell lines. Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking nontranscribed sequences. DNA sequences derived from the SV40 splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements.

10 The polypeptide can be recovered and purified from recombinant cell cultures by methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin
15 chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps.

The polypeptides of the present invention may be a naturally purified product, or a product of chemical synthetic procedures, or produced by
20 recombinant techniques from a prokaryotic or eukaryotic host (for example, by bacterial, yeast, higher plant, insect and mammalian cells in culture). Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be
25 non-glycosylated. Polypeptides of the invention may also include an initial methionine amino acid residue.

The polypeptides of the present invention, when utilized for clinically related purposes, may also be suspended in a pharmacologically
30 acceptable diluent or excipient to facilitate such uses, which will include

use as a vaccine for the purpose of preventing a wide variety of streptococcal and staphylococcal infections.

In accordance with another aspect of the present invention, there is provided a vaccine that includes at least one polypeptide that is at least 75% identical, preferably at least 90% identical and most preferably 95% identical, to a polypeptide sequence comprising the sequence of SEQ ID NO: 2, 4, or 6. Such variations in homology for putative vaccines are well known in the art (See, for example, Hanson et al., "Active and Passive Immunity Against *Borrelia burgdorferi* Decorin Binding Protein A (DbpA)," Infection and Immunity, (May) 1998, p. 2143 - 2153; Roberts et al., "Heterogeneity Among Genes Including Decorin Binding Proteins A and B of *Borrelia burgdorferi sensu lato*," Infection and Immunity, (Nov) 1998, p. 5275-5285). Such observations would similarly apply to portions, segments or fragments of the polypeptides disclosed herein.

Such segments find a multitude of uses. For example, such segments of the polypeptides according to the present invention find use as intermediates in the synthesis of higher molecular weight structures also within the present invention.

The term "active fragment" means a fragment that generates an immune response (i.e., has immunogenic activity) when administered, alone or optionally with a suitable adjuvant, to an animal, such as a mammal, for example, a rabbit or a mouse, and also including a human.

In accordance with a further aspect of the invention, a vaccine of the type hereinabove described is administered for the purpose of preventing or treating infection caused by streptococci and staphylococci as well as many related organisms.

A vaccine in accordance with the present invention may include one or more of the hereinabove described polypeptides or active fragments thereof. When employing more than one polypeptide or active fragment, such as two or more polypeptides and/or active fragments may be used as
5 a physical mixture or as a fusion of two or more polypeptides or active fragments. The fusion fragment or fusion polypeptide may be produced, for example, by recombinant techniques or by the use of appropriate linkers for fusing previously prepared polypeptides or active fragments.

10 In many cases, the variation in the polypeptide or active fragment is a conservative amino acid substitution, although other substitutions are within the scope of the invention.

In accordance with the present invention, a polypeptide variant
15 includes variants in which one or more amino acids are substituted and/or deleted and/or inserted.

In another aspect, the invention relates to passive immunity vaccines formulated from antibodies against a polypeptide or active fragment of a
20 polypeptide of the present invention. Such passive immunity vaccines can be utilized to prevent and/or treat streptococcal and staphylococcal infections in patients. In this manner, according to a further aspect of the invention, a vaccine can be produced from a synthetic or recombinant polypeptide of the present invention or an antibody against such
25 polypeptide.

Still another aspect the present invention relates to a method of using one or more antibodies (monoclonal, polyclonal or sera) to the polypeptides of the invention as described above for the prophylaxis and/or treatment of
30 diseases that are caused by streptococcal and staphylococcal bacteria. In particular, the invention relates to a method for the prophylaxis and/or

treatment of infectious diseases that are caused by streptococci and staphylococci. In a still further preferred aspect, the invention relates to a method for the prophylaxis and/or treatment of such diseases as necrotizing fasciitis, scarlet fever, sepsis and many diseases of newborns, in humans
5 by utilizing a vaccine of the present invention.

Generally, vaccines are prepared as injectables, in the form of aqueous solutions or suspensions. Vaccines in an oil base are also well known such as for inhaling. Solid forms which are dissolved or suspended
10 prior to use may also be formulated. Pharmaceutical carriers, diluents and excipients are generally added that are compatible with the active ingredients and acceptable for pharmaceutical use. Examples of such carriers include, but are not limited to, water, saline solutions, dextrose, or glycerol. Combinations of carriers may also be used.

15 Vaccine compositions may further incorporate additional substances to stabilize pH, or to function as adjuvants, wetting agents, or emulsifying agents, which can serve to improve the effectiveness of the vaccine.

20 Vaccines are generally formulated for parenteral administration and are injected either subcutaneously or intramuscularly. Such vaccines can also be formulated as suppositories or for oral administration, using methods known in the art, or for administration through nasal or respiratory routes.

25 The amount of vaccine sufficient to confer immunity to pathogenic bacteria is determined by methods well known to those skilled in the art. This quantity will be determined based upon the characteristics of the vaccine recipient and the level of immunity required. Typically, the amount
30 of vaccine to be administered will be determined based upon the judgment of a skilled physician. Where vaccines are administered by subcutaneous or

intramuscular injection, a range of 0.5 to 500 μ g purified protein may be given.

5 The present invention is also directed to a vaccine in which a polypeptide or active fragment of the present invention is delivered or administered in the form of a polynucleotide encoding the polypeptide or active fragment, whereby the polypeptide or active fragment is produced *in vivo*. The polynucleotide may be included in a suitable expression vector and combined with a pharmaceutically acceptable carrier.

10 Thus, the present invention expressly contemplates a vaccine composition comprising any of the polypeptides disclosed herein, said polypeptide being present in an amount effective to produce an immune response, and wherein said polypeptide is suspended in a pharmacologically acceptable carrier, diluent or excipient.

15 The vaccine compositions of the present invention may also comprise live vaccines, containing such organisms as *Streptococcus gordoniae* and *Salmonella typhi*, wherein said organisms contain recombinant polypeptides as disclosed herein.

20 In addition, the polypeptides of the present invention can be used as immunogens to stimulate the production of antibodies for use in passive immunotherapy, for use as diagnostic reagents, and for use as reagents in other processes such as affinity chromatography.

25 Thus, the present invention is also directed to methods for the prevention of a wide variety of diseases caused by streptococcal and staphylococcal organisms, said methods involving the administering of vaccines disclosed herein to animals at risk of such diseases, especially where said animals are humans.

In addition, the invention disclosed herein is also directed to a means of treating animals, especially humans, afflicted with a disease caused by the organisms from which the isolated polypeptides of the invention are derived, such methods including, but not being limited to, administering to an animal, especially a human, afflicted with such a disease of a therapeutically effective amount of an antibody, or mixture of antibodies, against the polypeptides disclosed herein.

Antibodies specific for the polypeptides disclosed herein may be either polyclonal or monoclonal and may even be in the form of antisera. When such antibodies are monoclonal in nature, they may be produced by conventional methods of preparing monoclonal antibodies, such as from conventional hybridoma cells, and may also be produced by genetically engineered cells transformed with vectors containing genes specifically coding for the different heavy and light chains of antibody molecules having an arrangement of variable regions specifically complementary to one or more of the polypeptides of the invention. Such recombinantly produced antibodies may be in the form of either dimers or tetramers, depending on the type of cellular expression system utilized therefor.

The invention will now be further described in more detail in the following non-limiting examples and it will be appreciated that additional and different embodiments of the teachings of the present invention will doubtless suggest themselves to those of skill in the art and such other embodiments are considered to have been inferred from the disclosure herein.

Example 1

Southern Blot Analysis of Chromosomal DNA Using Probes Specific for the Sp36 Gene of *Streptococcus pneumoniae*

5 Genomic DNA was isolated from *Staphylococcus aureus*,
Streptococcus pyogenes (group A), and *Streptococcus agalactiae* (group B)
after overnight growth of the bacteria. The DNA was digested to
completion by overnight incubation with restriction enzymes (*Bam*HI and
10 *Pvu*II), and then DNA fragments were resolved by size by agarose gel
electrophoresis before transfer to a nylon membrane. The membrane was
then probed with DNA encoding the entire Sp36 open reading frame that
had been fluorescein-labeled with random primers using a kit from
Amersham Pharmacia Biotech Inc. The hybridization and washes were
15 carried out under low stringency conditions (i.e., 45°C, 5xSSC
hybridization; 45°C, 1xSSC for 1st wash; 45°C, 0.5xSSC for 2nd wash).
Here, SSC is composed of 150 mM NaCl and 15 mM sodium citrate, pH 7.0
and all washes are 50 mL each.

20 After hybridization and washing was complete, the bound,
fluorescein-labeled probe was detected using an anti-fluorescein antibody as
per the manufacturer's instructions with the kit. Similarly digested DNA
from *Streptococcus pneumoniae* strain SJ2 (serotype 6B) was used as a
positive control. Fluorescein-labeled bacteriophage lambda DNA digested
25 with the restriction nuclease *Hind*III was used as a size marker.

 The Sp36 probe hybridized with a single fragment in the digested *S.*
aureus DNA (~4.5 kb *Bam*HI fragment, ~5 kb *Pvu*II fragment) and with 2
major fragments in a *Pvu*II digest of serotype M1 of the group A
30 streptococci genomic DNA (~4.0 kb, and ~4.2 kb).

Example 2

BLAST Analysis Using Sp36 Predicted Amino Acid Sequence

Sequence comparisons of the Sp36 encoded protein sequence against the publicly available GenBank sequence database (including the unfinished microbial database (<http://www.ncbi.nlm.nih.gov/BLAST/unfinishedgenome.html>)) revealed two highly homologous amino acid sequences. One of these was a predicted amino acid sequence from the *S. pyogenes* genome. This predicted polypeptide comprised 825 amino acid residues (MW = 92,616 Da) that was 25.1% identical to the Sp36 amino acid sequence from pneumococcus serotype 4 but maintained the 5 histidine triads (underlined in Figure 5(a) - SEQ ID NO: 2). The second polypeptide encoded within the *S. pyogenes* database contained several errors that were corrected by our sequencing of this region of the genome. The DNA fragment obtained encoded a protein of 792 amino acids (MW = 87,457 Da) that was 12.6% identical to the pneumococcal sequence and 12.5% identical to the first *S. pyogenes* polypeptide. This predicted amino acid sequence contained four histidine triad motifs (underlined in Fig. 5(b) - SEQ ID NO.: 4). The third polypeptide sequence obtained was one already in the database (Accession No. AF062533) and identified only as an unknown gene downstream from a gene identified as *lmb* in *S. galactiae*. This 822 amino acid protein thus has a predicted molecular weight of 92,353 Da and maintains the 5 histidine triad motifs (underlined in Figure 5(C) - SEQ ID NO: 6). This second polypeptide shows 25.6% sequence identity to Sp36 of pneumococcus type 4 and 97.7% and 11.6% identity to the two group A homologs, respectively.

Example 3

Southern Blot Analysis Using a group A Streptococcal Sp36 Homolog Probe

5 Southern blot analysis was performed with a fluorescein-labeled DNA fragment as probe, which encoding a group A streptococcal Sp36 homolog cloned from an M1 serotype of the group A streptococcal genome. This fragment was then used to probe genomic DNA from an M6 serotype of the group A streptococcal genome, as well as serotype 1a and serotype 3 of
10 the group B streptococcal genome, and strain SJ2 (serotype 6B) of pneumococcus. In all cases, a single band was obtained in DNA digested with *Bam*HI when hybridization was carried out under low stringency conditions (as described above). A band of about 20 kb was visualized in group A streptococcal DNA, about 4.5 kb was obtained for group B
15 streptococcal DNA, and a band of about 4kb was seen for pneumococcus.

Example 4

20

Western Blot Analysis of Reactivity of group B Streptococcal Homolog With Anti-Pneumococcal Sp36 Antiserum

To determine whether antiserum raised against recombinant Sp36
25 from *S. pneumoniae* would recognize the recombinant Sp36 homolog encoded by group B streptococcal organisms, a western blot was performed. One hundred nanograms (100 ng) of recombinant Sp36 polypeptide cloned from either *S. pneumoniae* serotype 4, or of the Sp36 homolog cloned from group B streptococcal organisms, or from an unrelated
30 recombinant protein control expressed and purified in the same way, were subjected to SDS-PAGE containing 12% acrylamide. A cell lysate of

pneumococcal strain SJ2 (serotype 6B) was also included on the gel. After electrophoresis, the separated proteins were transferred to a nitrocellulose membrane and probed with rabbit polyclonal antiserum raised against the recombinant pneumococcal protein. Bound antibodies were detected
5 chemiluminescently with a goat anti-rabbit IgG antibody conjugated to horseradish peroxidase using the substrate ECL (from Amersham). The results demonstrate that antiserum raised against the pneumococcal Sp36 protein cross-react with the Sp36 homolog identified from the group B streptococci and thereby indicating conservation of epitopes between the
10 proteins. The group B streptococcal homolog is also approximately the same size as the protein detected in *S. pneumoniae* lysates. Because the group A and B homologs are highly homologous, if not identical, such antiserum would also likely cross-react with the group A streptococcal protein.

15

Example 5

Alignment of Predicted Amino Acid Sequences of the Sp36 Homologs from group A and B Streptococci With Pneumococcal Sp36

20

The predicted amino acid sequences from the Sp36 genes from group A and group B streptococci and *S. pneumoniae* were aligned using the Clustal algorithm in a DNASTar Computer package (DNASTar, Inc., Madison, WI). Amino acids that match those encoded by the pneumococcal
25 gene are boxed in Figure 2 (showing the results of the alignment). Gaps introduced in the sequence by the alignment process are indicated by dashed lines.

30

Example 6

Percentage Sequence Identity Between Homologs of Sp36

The Sp36 amino acid sequence from pneumococci is 25.6% identical to the predicted amino acid sequence of the homologous gene of group B streptococci and 25.1% and 12.6% identical to the deduced sequences of the two genes from group A streptococci. Furthermore, the group B homolog is 97.7% and 11.6% identical to the first (GAS36) and second (GAS36(2)) homologs from group A streptococci, respectively. These experiments indicate that homologous genes to Sp36 from pneumococcus are present in group A and group B streptococci, as well as in *Staphylococcus aureus*. The protein encoded by this gene may therefore perform a similar function in these different organisms. This suggests that a vaccine comprising one or more of these proteins may be broadly protective against these species. These results are summarized in Table 1 which shows the percent identity between the amino acid sequences of Sp36 from pneumococcus strain Norway 4 (serotype 4), group A streptococci Sp36 homolog from an M1 serotype, and group B streptococci Sp36 from strain R268.

Table 1.

	Pneumo. Sp36	GAS36	GAS36(2)	GBS36
Pneumo. Sp36	100%	25.1%	12.6%	25.6%
GAS36	---	100%		97.7%
GAS36(2)	---	---	100%	11.6%
GBS36	---	---		100%

where GAS36 = SEQ ID NO: 2
 GAS36(2) = SEQ ID NO: 4
 GBS36 = SEQ ID NO: 6

WHAT IS CLAIMED IS:

1. An isolated polypeptide comprising an amino acid sequence at least 75% identical to a sequence selected from the group consisting of SEQ ID NO: 2, 4 and 6.
2. The isolated polypeptide of claim 1 wherein said polypeptide is at least 90% identical to the sequence selected from the group consisting of SEQ ID NO: 2, 4, and 6.
3. The isolated polypeptide of claim 1 wherein said polypeptide is at least 95% identical to the sequence selected from the group consisting of SEQ ID NO: 2, 4, and 6.
4. The isolated polypeptide of claim 1 wherein said polypeptide has the amino acid sequence selected from the group consisting of SEQ ID NO: 2, 4 and 6.
5. The isolated polypeptide of claim 1 wherein said polypeptide is found in an organism selected from the group consisting of group A streptococci, group B streptococci, and *Staphylococcus aureus*.
6. The isolated polypeptide of claim 5 wherein the group A streptococcal organism is *Streptococcus pyogenes*.
7. The isolated polypeptide of claim 5 wherein the group B streptococcal organism is *Streptococcus agalactiae*.
8. The isolated polypeptide of claim 1 wherein said polypeptide has a sequence at least 25% identical to the amino acid sequence of the Sp36 protein of *Streptococcus pneumoniae*.

9. An isolated polynucleotide comprising a sequence coding for a polypeptide selected from the group consisting of the polypeptides of claims 1, 2, 3, 4, 5, 6, 7, and 8.

5

10. The isolated polynucleotide of claim 9 wherein said polynucleotide has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, 3 and 5.

10

11. An antibody specific for a polypeptide selected from the group consisting of the polypeptides of claims 1, 2, 3, 4, 5, 6, 7, and 8.

12. The antibody of claim 11 wherein said antibody is a monoclonal antibody.

15

13. A genetically engineered cell producing the antibody of claim 12.

14. A vector comprising the polynucleotide of claim 9.

20

15. A vector comprising the polynucleotide of claim 10.

16. A genetically engineered cell expressing the polypeptide coded for by the polynucleotide of claim 9 or 10.

25

17. A composition comprising a polypeptide selected from the group consisting of the polypeptides of claims 1, 2, 3, 4, 5, 6, 7, and 8, said polypeptide being suspended in a pharmacologically acceptable diluent or excipient.

30

18. A vaccine composition comprising a polypeptide selected from the group consisting of the polypeptide of claims 1, 2, 3, 4, 5, 6, 7, and 8,

said polypeptide being present in an amount effective to produce an immune response, and wherein said polypeptide is suspended in a pharmacologically acceptable carrier, diluent or excipient.

5 19. A vaccine comprising an immunogenically active amount of the composition of claim 17.

10 20. A method of vaccinating an animal against infection by a bacterial organism selected from the group consisting of streptococcal bacteria and staphylococcal bacteria comprising administering to said animal an immunologically effective amount of the vaccine of claim 19.

21. The method of claim 20 wherein said animal is a human.

15 22. A method of treating a disease comprising administering to an animal afflicted therewith of a therapeutically effective amount of an antibody of claim 12 wherein said antibody is suspended in a pharmacologically acceptable carrier, diluent or excipient.

20 23. The method of claim 22 wherein said animal is a human.

24. The method of claim 22 wherein said disease is caused by an organism selected from the group consisting of group A streptococci, group B streptococci, and *Staphylococcus aureus*.

25

30


Figure 1

Figure 2(a)

		10	20	30																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																	</
--	--	----	----	----	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	----

Figure 2(b)

	340	350	360	
330	H V E E D G L I F E P T D V I K S N A F G Y V V P H G D H Y	Gas36.pro		
328	H V E E D G L I F E P T D V I K S N A F G Y V V P H G D H Y	Gbs36.PRD		
303	H V E S D G L V F D P A Q I T S R T A R G V A V P H G D H Y	Pneumo Sp36.PRD		
	370	380	390	
360	H I I P R S D L S P L E M E L A D - - - R Y L A G D - - -	Gas36.pro		
358	H I I P R S D L S P L E M E L A D - - - R Y L A G D - - -	Gbs36.PRD		
333	H F I P Y S D M S E L F E R T A R I I P L R Y R S N H W V P	Pneumo Sp36.PRD		
	400	410	420	
383	T E D D D S G S D H S K P S D K E V T H T F L G H R I K A Y	Gas36.pro		
381	T D D N D S G S D H S K P S D K E V T H T F L G H R I K A Y	Gbs36.PRD		
363	D S R P E Q P S P Q P T P E P S P G P D P A P N L K I D S N	Pneumo Sp36.PRD		
	430	440	450	
413	G K G L D G K P Y D T S D A Y V F S K E S I H S - V D K S G	Gas36.pro		
411	G K G L D G K P Y D T S D A Y V F S K E S I H S - V D K S G	Gbs36.PRD		
393	S S L V S Q L V R K V G E G Y V F F E E K G I S R Y V F A K D	Pneumo Sp36.PRD		
	460	470	480	
442	V T A K H G D H F H Y - I G F G E L E D Y E L D E V A N W V	Gas36.pro		
440	V T A K H G D H F H Y - I G F G E L E D Y E L D E V A N W V	Gbs36.PRD		
423	L P S E T V K N L E S K L S K D E S V S H T L T A K K E N V	Pneumo Sp36.PRD		
	490	500	510	
471	K A K G D A - - D E L A A A L D D E D G K E K P L F D T K K	Gas36.pro		
469	K A K G D A - - D E L V A A L D D E D G K E K P L F D T K K	Gbs36.PRD		
453	A P R D Q E F Y D K A Y N L L T E A H - - - K A L F E N K G	Pneumo Sp36.PRD		
	520	530	540	
499	V S R K V T K D G K V G Y M M P K D G K D Y F Y A R D D L D	Gas36.pro		
497	V S R K V T K D G K V G Y I M P K D G K D Y F Y A R Y D L D	Gbs36.PRD		
480	R N S D F Q A L D K L L E R L N D E S T N - - - K E K L V	Pneumo Sp36.PRD		
	550	560	570	
529	L T O I A F - - - A E D E L M L K D K K H Y R Y D I V D T	Gas36.pro		
527	L T O I A F - - - A E D E L M L K D K K H Y R Y D I V D T	Gbs36.PRD		
506	D Q L L A F L A P I T H P E R L G K P N S O I E Y T E D E V	Pneumo Sp36.PRD		
	580	590	600	
555	G I E P R L A - - - V D V S S L P M H A G N A T Y D T G S S	Gas36.pro		
553	G I E P R L A - - - V D V S S L P M H A G N A T Y D T G S S	Gbs36.PRD		
536	R I - A Q L A D K Y T T S D G Y I F D E H D I I S D E G D A	Pneumo Sp36.PRD		
	610	620	630	
582	F V I P H I D H I H V V P Y S W L T - R D D I A T I K Y V M	Gas36.pro		
580	F V I P H I D H I H V V P Y S W L T - R N O I A T I K Y V M	Gbs36.PRD		
565	Y V T P H M G H S H W I G K D S L S D K E K V A A Q A Y T K	Pneumo Sp36.PRD		
	640	650	660	
611	D H P E V R P - - - D I W S K P G H E E S G S V I P N V T	Gas36.pro		
609	D H P E V R P - - - D V W S K P G H E E S G S V I P N V T	Gbs36.PRD		
595	E K G I L P P S P D A D V K A N P T G D S A A A I Y N R V K	Pneumo Sp36.PRD		

670 680 690 Gas36.pro
637 P L O K R A G M P N W O - I I H S A E E V Q K A L A E G R F Gbs36.PRO
635 P L O K R A G M P N W O - I I H S A E E V Q K A L A E G R F Pneumo Sp36.PRO
625 G - E K R I P L V R L P Y M V E H T V E V K N G - - - - -

700 710 720 Gas36.pro
666 A T P D G Y I F D P R O V L A K E T F V W - K O G S F S I P Gbs36.PRO
664 A A P O G Y I F O P R D V L A K E T F V W - K D G S F S I P Pneumo Sp36.PRO
648 - - - - - N L I I P H K D H Y H N I K F A W F D H T Y K A P

730 740 750 Gas36.pro
695 R A O G S S L R T I - - - - - N K S O L S O A E Gbs36.PRO
693 R A O G S S L R T I - - - - - N K S O L S O A E Pneumo Sp36.PRO
674 - - - - - N G Y T L E D L F A T I K Y Y V E H P D E R P H S N D G

760 770 780 Gas36.pro
714 W O O A O E - L L A K K N A G D A T O T O - K P E E K O O A Gbs36.PRO
712 W O O A O E - L L A K K N A G D A T O T O - K P E E K O O A Pneumo Sp36.PRO
702 W G N A S E H V L G K K D H S E O P N K N F K A D E E P V E

790 800 810 Gas36.pro
742 O K S N E N O O P - - - S E A S K E E E K E S O O F I O S L Gbs36.PRO
740 D K S N E N O O P - - - S E A S K E E - K E S O D F I O S L Pneumo Sp36.PRO
732 E T P A E P E V P O V E T E K V E A O L K E A E V L L A K V

820 830 840 Gas36.pro
769 P O Y G L O R A T L E O H I N O L A O K A N I D P K Y L I F Gbs36.PRO
766 P O Y G L O R A T L E O H I N O L A O K A N I D P K Y L I F Pneumo Sp36.PRO
762 T D S S L - K A N A T E T L A G L R N N L T L Q - - - - I H

850 860 870 Gas36.pro
799 O P E G V O F Y N K N G E L V T Y - - - - D I K T L O O I N Gbs36.PRO
796 O P E G V O F Y N K N G E L V T Y - - - - D I K T L O O I N Pneumo Sp36.PRO
787 D N N S I H - - - A E A E K L L A L L K G S N P S S V S K E K

825 P
822 P
815 I N

Gas36.pro
Gbs36.PRO
Pneumo Sp36.PRO

Figure 3

S. pyogenes M1
S. pyogenes M6
S. agalactiae 090R
S. agalactiae 13/63
S. pneumoniae




Figure 4



Control

Sp36 GBS

Sp36

SJ2 6b

Figure 5(a)

```

MKKTYGYIGS VAAILLATHI GSYQLGKHHM GSATKDNQIA YIDDSKGKAK APKTNKTMDO ISAEEGISAE 70
QIVVKITDQG YVTSHGDHYH FYNCKVPYDA IISELLMTD PNYRFKQSDV INEILDGYVI KVNNGNYVYL 140
KPGSKRKNIR TKQQIAEQVA KGTKEAKEG LAQVAHLSKE EVAAVNEAKR QGRYTTDDGY IFSPTDIID 210
LGDAYLVPHG NHYHYIPKKD LSPSELAAQ AYWSQKQGRG ARPSDYRPTP APAPGRRKAP IPDVTIPNGQ 280
GHQPDNGGYH PAPRPNDAS QNKHORDEFK GKTFFKELLDQ LHRDLKCYRH VEEDGLIFEP TQVIKSNAFG 350
YVVPHGDDHYH IIPRSQLSPL EMELADRYLA QOTEDDDSGS DSKPSDKEV THTFGLHRIK AYKGGLDGKP 420
YDTSDAYVFS KESIHSVDKS GVTAKHGDHF HYIGFGELEQ YELDEVANWV KAKGOADELA AALDQEQGKE 490
KPLFDTKKVS RKVTGDKGVG YMPKDGKDY FYARDQLDLT QIAFAEQELM LKDKKHRYD IVDTGIEPRL 560
AVDVSSLPMPH AGNATYDTGS SFVIPHIDHI HVVPYSWLTR DQIATIKYVM QHPEVRPDIW SKPGHEESGS 630
VIPNVTPLDK RAGMPNWQII HSAEEVQKAL AGRFATPDG YIFDPRDLA KETFWWKDGS FSIPRADGSS 700
LRTINKSDL SQAEWQQAQEL LAKKNAGDAT DTDKPKEKQQ ADKSNENQQP SEASKEEKE SDDFIDSLPD 770
YGLDRATLED HINQLAQKAN IDPKYLIFQP EGVQFYFNKG ELVTYDIKTL QQINP 825

```

Figure 5(b)

```

MKTKKVILV GLLSSQLTL IACQSRGNGT YPIKTKQSRK GMTSNKIKPI KSKKTNKTH KGVAGVDFPT 70
DDGFILTKDS KILSKTDQGI VVDHGHSHF IFYADLKGSP FEYLIPKGAS LAKPAVAQRA ASQTSKVAD 140
PHHHYEFNPA DIVAEDALGY TVRHDDHFHY ILKSSLSGQT QAQAKQVATR LPQTSSLVST ATANGIPGLH 210
FPTSDFGFQFN GQGI VGT KD YLAEKL GIDP STIKRVETQD GKLGLEYPHH DHAHVLM LSD IEIGKDIPDP HAI EHARELE 350
REKEYQEKLA ALGFDEEVIL DIVRTHDAPT PFPSNEKDPN MMKEWLATVI KLDLGSRKDP LQKGLSLP 420
KHKVGMDTLR ALGDISPVLQ FKLLKQLLMT KITGVTDYRFL DNMPQLEGID ISQNNLKDIS FL SKYKNLTL 490
NLETLGIGFT IRPLGQLPNL KFLVLSNNKI SDLSPLASLH QLQELHIDNN QITDLSPVSH KESLTVVDLS 560
VAAADNGIED QAPKLETLMV NDTKVSHLDF LKNNPNLSSL SINRAQLQSL EGIEASSVIV RVEAEGNQIK 630
RNADVDLATL LTFLDVTGNQ LTSLEGVNNF TALDILSVSK NQLTNNVNL SK PNKTVTNIDI SHNNISLADL 700
SLVLKDKQGS IAKNFPAVYE GSMVGNGTAE EKAAMATKAK ESAQEASESH DYNHNHTYED EEGHAHEHRD 770
KLNQHIPEA ENEAKDEQNH AD
KDDHDHEHED

```

Figure 5(c)

MKKTYGYIGS VAAILLATHI GSYQLGKHHM GLATKDNQIA YIDDSKGKVK APKTNKTMQ ISAEEGISAE 70
 QIVVKITDQG YVTSHGHDYH FYNGKVPYDA IISEELLMTD PNYHFKQSDV INEILDGYVI KVNNGYVYVL 140
 KPGSKRKNIR TKQOIAEQVA KGTKEAKEG LAQVAHLSKE EVAAVNEAKR QGRYTTDDGY IFSPTDIIDD 210
 LGDAYLVPHG NHYHYIPKLD LSPSELAAAQ AYWSQKQGRG ARPSDYRPTP APGRRKAPIP DVTPNPGQGH 280
 QPDNGGYHPA PPRPNDASQN KHQRDEFKKG TFKELLDQLH RLDLKVRHVE EDGLIFEPTQ VIKSNAFGYV 350
 VPHGDHYHII PRSOLSPLEM ELADRYLAGQ TDDNDSGSDH SKPSDKEVTH TFLGHRIRKAY GKGLDGKPYD 420
 TSDAYVFSKE SIHSVDKSGV TAKHGDHFHY IGFGELEQYE LDEVANWVKA KGQADELVAA LDQEQGKEKP 490
 LFDTKKVS RK VTKDGKVGVI MPKDGKDYFY ARYQLDLTQI AFAGEQELMLK DKKHYRYDIV DTGIEPRLAV 560
 DVSSLPMHAG NATYDTGSSF VIPHIDHIHV VPYSWLTRNQ IATIKYVMQH PEVRPVDVWSK PGHEESGGSVI 630
 PNVTPLDKRA GMPNWNQIIHS AEEVQKALAE GRFAAPDGYI FPRDVLAK E TFWNKDGSFS IPRADGSSLR 700
 TINKSDLSQA EWQQAQELIA KKNAGDATDT DKPEEKQQAAD KSNENQQPSE ASKEEKESDD FIDSLPDYGL 770
 DRATLEDHIN QLAQKANIDP KYLLIFQPEGV QFYNNKGELV TYDIKTLOQI NP 822

WO 01/14421

SEQUENCE LISTING

<110> Heinrichs, Jon
Johnson, Leslie S.
Koenig, Scott
Adamou, John E.

<120> Pneumococcal Protein Homologs and Fragments for
Vaccines

<130> 469201-402

<140>

<141>

<150> U.S. 60/150,750

<151> 1999-08-25

<160> 6

<170> PatentIn Ver. 2.1

<210> 1

<211> 2478

<212> DNA

<213> Streptococcus pyogenes

<400> 1
gtgaagaaaa catatgggta tateggctca gttgctgcta ttttactagc tactcatatt 60
ggaagttacc aacttggtta gcatcatatg gggtcagcaa caaaggacaa tcaaattgcc 120
tatattgatg atagcaaagg taaggcaaaa gcccttaaaa caaacaaaac gatggatcaa 180
atcagtgctg aagaaggcat ctctgctgaa cagatcgtag tcaaaattac tgaccaaggc 240
tatgtgacct cacatgggtga ccattatcat ttttacaatg ggaaagttcc ttatgatgcg 300
attattagtg aagagttggt gatgacggat cctaattacc gttttaaaca atcagacggt 360
atcaatgaaa tcttagacgg ttacgttatt aaagtcaatg gcaactatta tgtttacctc 420
aagccaggta gcaagcgcaa aaacattcga accaaacaac aaattgctga gcaagtagcc 480
aaaggaacta aagaagctaa agaaaaaggt ttagctcaag tggcccatct cagtaaagaa 540
gaagttgcgg cagtcaatga agcaaaaaga caaggacgct atactacaga cgatggctat 600
atTTTTtagtc cgacagatat cattgatgat ttaggagatg cttatttagt acctcatggt 660
aatcactatc attatatctc taaaaaggat ttgtctccaa gtgagctagc tgctgcacaa 720
gcctactgga gtcaaaaaca aggtcgaggt gctagaccgt ctgattaccg cccgacacca 780
gccccagccc caggctcgtag gaaagcccca attcctgatg tgacgcctaa ccctggacaa 840
ggtcacagc cagataacgg tggctatcat ccagcgctc ctaggccaaa tgatgctca 900
caaaaacaac accaaagaga tgagttttaa ggaaaaacct ttaaggaact ttagatcaa 960
ctacaccgtc ttgatttgaa ataccgtcat gtggaagaag atgggttgat ttttgaaccg 1020
actcaagtga tcaaatcaaa cgcttttggt tatgtggtgc ctcatggaga tcattatcat 1080
attatcccaa gaagtcagtt atcacctctt gaaatggaat tagcagatcg atacttagcc 1140
ggccaaactg aggacgatga ctcaggttca gatcactcaa aaccatcaga taaagaagtg 1200
acacatacct ttcttggtca tcgcatcaaa gcttacggaa aaggcttaga tggtaaacca 1260
tatgatacga gtgatgctta tgtttttagt aaagaatcca ttcatcagt ggataaatca 1320
ggagttacag ctaaacacgg agatcatttc cactatatag gatttgaga acttgaacaa 1380
tatgagttgg atgaggtcgc taactgggtg aaagcaaaag gtcaagctga tgagcttgct 1440
gctgctttgg atcaggaaca aggcaaagaa aaaccactct ttgacactaa aaaagtgaag 1500
cgcaaagtga caaaagatgg taaagtgggc tatatgatgc caaaagatgg caaggactat 1560
ttctatgctc gtgatcaact tgatttgact cagattgcct ttgccgaaca agaactaatg 1620
cttaaagata agaaacatta cgttatgac attgttgaca caggattga gccacgactt 1680
gctgtagatg tgtcaagtct gccgatgcac gctggtaatg ctacttacga tactggaagt 1740
tcgtttgtta tccctcatat tgatcatatc catgtcgttc cgtattcatg gttgacgcgc 1800
gatcagattg caacaatcaa gtatgtgatg caacaccccg aagttcgtcc ggatatatgg 1860

WO 01/14421

tctaagccag ggcatagaaga gtcagggttcg gtcattccaa atgttacgcc tcttgataaa 1920
 cgtgctggta tgccaaactg gcaaattatc cattctgctg aagaagttca aaaagcccta 1980
 gcagaagggtc gttttgcaac accagacggc tatattttcg atccacgaga tgttttggcc 2040
 aaagaaactt ttgtatggaa agatggctcc tttagcatcc caagagcaga tggcagttca 2100
 ttgagaacca ttaataaatc tgatctatcc caagctgagt ggcaacaagc tcaagagtta 2160
 ttggcaaaga aaaacgctgg tgatgctact gatacggata aacccaaaga aaagcaacag 2220
 gcagataaga gcaatgaaaa ccaacagcca agtgaagcca gtaagaaga agaaaaagaa 2280
 tcagatgact ttatagacag tttaccagac tatggcttag atagagcaac cctagaagat 2340
 catatcaatc aattagcaca aaaagctaat atcgatccta agtatctcat tttccaacca 2400
 gaagggtgcc aattttataa taaaaatggt gaattggtaa cttatgatat caagacactt 2460
 caacaaataa acccttaa 2478

<210> 2

<211> 825

<212> PRT

<213> Streptococcus pyogenes

<400> 2

Val Lys Lys Thr Tyr Gly Tyr Ile Gly Ser Val Ala Ala Ile Leu Leu
 1 5 10 15
 Ala Thr His Ile Gly Ser Tyr Gln Leu Gly Lys His His Met Gly Ser
 20 25 30
 Ala Thr Lys Asp Asn Gln Ile Ala Tyr Ile Asp Asp Ser Lys Gly Lys
 35 40 45
 Ala Lys Ala Pro Lys Thr Asn Lys Thr Met Asp Gln Ile Ser Ala Glu
 50 55 60
 Glu Gly Ile Ser Ala Glu Gln Ile Val Val Lys Ile Thr Asp Gln Gly
 65 70 75 80
 Tyr Val Thr Ser His Gly Asp His Tyr His Phe Tyr Asn Gly Lys Val
 85 90 95
 Pro Tyr Asp Ala Ile Ile Ser Glu Glu Leu Leu Met Thr Asp Pro Asn
 100 105 110
 Tyr Arg Phe Lys Gln Ser Asp Val Ile Asn Glu Ile Leu Asp Gly Tyr
 115 120 125
 Val Ile Lys Val Asn Gly Asn Tyr Tyr Val Tyr Leu Lys Pro Gly Ser
 130 135 140
 Lys Arg Lys Asn Ile Arg Thr Lys Gln Gln Ile Ala Glu Gln Val Ala
 145 150 155 160
 Lys Gly Thr Lys Glu Ala Lys Glu Lys Gly Leu Ala Gln Val Ala His
 165 170 175
 Leu Ser Lys Glu Glu Val Ala Ala Val Asn Glu Ala Lys Arg Gln Gly
 180 185 190
 Arg Tyr Thr Thr Asp Asp Gly Tyr Ile Phe Ser Pro Thr Asp Ile Ile
 195 200 205
 Asp Asp Leu Gly Asp Ala Tyr Leu Val Pro His Gly Asn His Tyr His

WO 01/14421

210 215 220
 Tyr Ile Pro Lys Lys Asp Leu Ser Pro Ser Glu Leu Ala Ala Ala Gln 240
 225 230 235
 Ala Tyr Trp Ser Gln Lys Gln Gly Arg Gly Ala Arg Pro Ser Asp Tyr 255
 245 250
 Arg Pro Thr Pro Ala Pro Ala Pro Gly Arg Arg Lys Ala Pro Ile Pro 270
 260 265
 Asp Val Thr Pro Asn Pro Gly Gln Gly His Gln Pro Asp Asn Gly Gly 285
 275 280
 Tyr His Pro Ala Pro Pro Arg Pro Asn Asp Ala Ser Gln Asn Lys His 300
 290 295
 Gln Arg Asp Glu Phe Lys Gly Lys Thr Phe Lys Glu Leu Leu Asp Gln 320
 305 310 315
 Leu His Arg Leu Asp Leu Lys Tyr Arg His Val Glu Glu Asp Gly Leu 335
 325 330
 Ile Phe Glu Pro Thr Gln Val Ile Lys Ser Asn Ala Phe Gly Tyr Val 350
 340 345
 Val Pro His Gly Asp His Tyr His Ile Ile Pro Arg Ser Gln Leu Ser 365
 355 360
 Pro Leu Glu Met Glu Leu Ala Asp Arg Tyr Leu Ala Gly Gln Thr Glu 380
 370 375
 Asp Asp Asp Ser Gly Ser Asp His Ser Lys Pro Ser Asp Lys Glu Val 400
 385 390 395
 Thr His Thr Phe Leu Gly His Arg Ile Lys Ala Tyr Gly Lys Gly Leu 415
 405 410
 Asp Gly Lys Pro Tyr Asp Thr Ser Asp Ala Tyr Val Phe Ser Lys Glu 430
 420 425
 Ser Ile His Ser Val Asp Lys Ser Gly Val Thr Ala Lys His Gly Asp 445
 435 440
 His Phe His Tyr Ile Gly Phe Gly Glu Leu Glu Gln Tyr Glu Leu Asp 460
 450 455
 Glu Val Ala Asn Trp Val Lys Ala Lys Gly Gln Ala Asp Glu Leu Ala 480
 465 470 475
 Ala Ala Leu Asp Gln Glu Gln Gly Lys Glu Lys Pro Leu Phe Asp Thr 495
 485 490
 Lys Lys Val Ser Arg Lys Val Thr Lys Asp Gly Lys Val Gly Tyr Met 510
 500 505
 Met Pro Lys Asp Gly Lys Asp Tyr Phe Tyr Ala Arg Asp Gln Leu Asp 525
 515 520

WO 01/14421

Leu Thr Gln Ile Ala Phe Ala Glu Gln Glu Leu Met Leu Lys Asp Lys
 530 535 540
 Lys His Tyr Arg Tyr Asp Ile Val Asp Thr Gly Ile Glu Pro Arg Leu
 545 550 555 560
 Ala Val Asp Val Ser Ser Leu Pro Met His Ala Gly Asn Ala Thr Tyr
 565 570 575
 Asp Thr Gly Ser Ser Phe Val Ile Pro His Ile Asp His Ile His Val
 580 585 590
 Val Pro Tyr Ser Trp Leu Thr Arg Asp Gln Ile Ala Thr Ile Lys Tyr
 595 600 605
 Val Met Gln His Pro Glu Val Arg Pro Asp Ile Trp Ser Lys Pro Gly
 610 615 620
 His Glu Glu Ser Gly Ser Val Ile Pro Asn Val Thr Pro Leu Asp Lys
 625 630 635 640
 Arg Ala Gly Met Pro Asn Trp Gln Ile Ile His Ser Ala Glu Glu Val
 645 650 655
 Gln Lys Ala Leu Ala Glu Gly Arg Phe Ala Thr Pro Asp Gly Tyr Ile
 660 665 670
 Phe Asp Pro Arg Asp Val Leu Ala Lys Glu Thr Phe Val Trp Lys Asp
 675 680 685
 Gly Ser Phe Ser Ile Pro Arg Ala Asp Gly Ser Ser Leu Arg Thr Ile
 690 695 700
 Asn Lys Ser Asp Leu Ser Gln Ala Glu Trp Gln Gln Ala Gln Glu Leu
 705 710 715 720
 Leu Ala Lys Lys Asn Ala Gly Asp Ala Thr Asp Thr Asp Lys Pro Lys
 725 730 735
 Glu Lys Gln Gln Ala Asp Lys Ser Asn Glu Asn Gln Gln Pro Ser Glu
 740 745 750
 Ala Ser Lys Glu Glu Glu Lys Glu Ser Asp Asp Phe Ile Asp Ser Leu
 755 760 765
 Pro Asp Tyr Gly Leu Asp Arg Ala Thr Leu Glu Asp His Ile Asn Gln
 770 775 780
 Leu Ala Gln Lys Ala Asn Ile Asp Pro Lys Tyr Leu Ile Phe Gln Pro
 785 790 795 800
 Glu Gly Val Gln Phe Tyr Asn Lys Asn Gly Glu Leu Val Thr Tyr Asp
 805 810 815
 Ile Lys Thr Leu Gln Gln Ile Asn Pro
 820 825

<210> 3

WO 01/14421

<211> 2379

<212> DNA

<213> Streptococcus pyogenes

<400> 3

atgaaaacga aaaaagtat tattttagtt ggtctattgt tatcatctca gttgactttg 60
 atagcttgct aatcacgagg taatggtaca tatcccatta aaacgaaaca atcacgtaag 120
 ggaatgacgt caaacaaaat taaaccgatt aaaaaaagca aaaagacaaa caagactcac 180
 aaaggtgtgg cgggtgtcga ttttcctaca gatgatgggt ttattttaac caaagactca 240
 aaaaatcttat caaaaacaga tcaggggaatc gttggtgacc atgatgggtca ttcgcatttt 300
 attttttatg ccgattttaa gggaagtcca tttgaatacc ttattccaaa aggagcaagt 360
 ttagctaagc cagctgttgc tcagcgagca gctagtcaag ggacttctaa agtagcagat 420
 cctcatcacc attatgaatt taaccacgag gatattgtgg ctgaagatgc tttaggctac 480
 acggttcgcc acgatgatca cttccattat attttgaagt caagcttacc aggtcagaca 540
 caggcacaaag ctaaacaggt tgctactcgc ttgccacaaa ccagtagcct tgtttcaaca 600
 gctacagcta atggtatttc aggtctgcat ttcccacact cagatgggtt tcaatttaac 660
 ggtcaaggta ttggtggggg aacaaaagac agtatttttag tggaccacga tggctactta 720
 catcctattt cttttgcgga cttcgtcag ggtggctggg cacatgtggc agatcaatac 780
 gatccccgta aaaaagcaga aaagccagca gaaacccatc agacaccaga gctatctgaa 840
 cgtgaaaagg aataccaaga aaaattagct tatttggcag aaaaattggg gattgatcca 900
 tcaactatta aacgtgtgga aacacaagac ggtaaaactg gtttgggaata cccatcaccat 960
 gaccacgcac acgtattgat gttatctgat attgaaatcg gaaaagacat tccagatcca 1020
 catgctattg agcatgccc tgaattggaa aaacataagg ttggaatgga taccttgcgt 1080
 gccttagggg ttgatgaaga agtgattttg gatctcgttc gcaactacga tgctccaacc 1140
 ccattcccat caaatgaaaa agatccgaat atgatgaaag aatgggttagc aacgggtatc 1200
 aaacttgact tgggcagccg taaagatcct ttgcaacgta aaggactttc actgttacc 1260
 aacttagaaa ctttaggaat tggtcttaca ccaatcaaag atatctcacc tgttttgcaa 1320
 tttaaaaaat tgaaacagtt gttaatgaca aaaacagggg tgactgatta tagatttttg 1380
 gataatatgc cacagttaga aggcattgat atttcacaaa acaatctcaa agatattagt 1440
 tttctgagca aatataaaaa cttaactcta gtacgggctg ctgataatgg tattgaagat 1500
 attagggcgc ttggtcaatt accaaatctc aaattcctcg tattgagtaa caataagatt 1560
 tctgatttaa gccactggc atcgttacat caattgcaag aattgcacat tgataataat 1620
 cagattacag atttaagccc tggttctcat aaagaatcat tgacgggtgt tgatttatca 1680
 agaaatgctg atgttgactt agcaacactt caagcaccga aattagaaac gttaatggtc 1740
 aatgatacca aggtttctca tttggatttc ttgaaaaata atcctaactc atctagccta 1800
 tctattaacc gtgcgcaatt gcaatctctt gaaggtattg aagcaagtag cgtcattgtc 1860
 agagtagaag cagaaggtaa ccaaattaaa tcgcttggtc ttagaaggtgt taataatttt 1920
 cttactttct tggatgtgac aggcacaccag ttgacttctc tagaaggtgt cctatctaaa 1980
 acagcacttg acattttaag cgtgtctaaa aaccaattaa caaatgtcaa cctatctaaa 2040
 cccaataaga cagttactaa cattgatatt agtcataaca atatctcatt agcagacctt 2100
 aaattgaacg agcaacatat tccagaagcc attgcgaaaa acttcccagc gggttacgaa 2160
 ggttctatgg taggtaatgg aacagctgaa gaaaaagcag ctatggctac taaggcgaaa 2220
 gaaagtgtc aagaagcatc ggaatcacat gactacaacc ataatacat ctatgaagat 2280
 gaagaaggtc atgctcacga gcacagagac aaagatgatc acgacatga acatgaggat 2340
 gaaaatgaag ctaaagatga gcaaaacat gctgactaa 2379

<210> 4

<211> 792

<212> PRT

<213> Streptococcus pyogenes

<400> 4

Met Lys Thr Lys Lys Val Ile Ile Leu Val Gly Leu Leu Leu Ser Ser
 1 5 10 15
 Gln Leu Thr Leu Ile Ala Cys Gln Ser Arg Gly Asn Gly Thr Tyr Pro
 20 25 30

WO 01/14421

Ile Lys Thr Lys Gln Ser Arg Lys Gly Met Thr Ser Asn Lys Ile Lys
 35 40 45
 Pro Ile Lys Lys Ser Lys Lys Thr Asn Lys Thr His Lys Gly Val Ala
 50 55 60
 Gly Val Asp Phe Pro Thr Asp Asp Gly Phe Ile Leu Thr Lys Asp Ser
 65 70 75 80
 Lys Ile Leu Ser Lys Thr Asp Gln Gly Ile Val Val Asp His Asp Gly
 85 90 95
 His Ser His Phe Ile Phe Tyr Ala Asp Leu Lys Gly Ser Pro Phe Glu
 100 105 110
 Tyr Leu Ile Pro Lys Gly Ala Ser Leu Ala Lys Pro Ala Val Ala Gln
 115 120 125
 Arg Ala Ala Ser Gln Gly Thr Ser Lys Val Ala Asp Pro His His His
 130 135 140
 Tyr Glu Phe Asn Pro Ala Asp Ile Val Ala Glu Asp Ala Leu Gly Tyr
 145 150 155 160
 Thr Val Arg His Asp Asp His Phe His Tyr Ile Leu Lys Ser Ser Leu
 165 170 175
 Ser Gly Gln Thr Gln Ala Gln Ala Lys Gln Val Ala Thr Arg Leu Pro
 180 185 190
 Gln Thr Ser Ser Leu Val Ser Thr Ala Thr Ala Asn Gly Ile Pro Gly
 195 200 205
 Leu His Phe Pro Thr Ser Asp Gly Phe Gln Phe Asn Gly Gln Gly Ile
 210 215 220
 Val Gly Val Thr Lys Asp Ser Ile Leu Val Asp His Asp Gly His Leu
 225 230 235 240
 His Pro Ile Ser Phe Ala Asp Leu Arg Gln Gly Gly Trp Ala His Val
 245 250 255
 Ala Asp Gln Tyr Asp Pro Ala Lys Lys Ala Glu Lys Pro Ala Glu Thr
 260 265 270
 His Gln Thr Pro Glu Leu Ser Glu Arg Glu Lys Glu Tyr Gln Glu Lys
 275 280 285
 Leu Ala Tyr Leu Ala Glu Lys Leu Gly Ile Asp Pro Ser Thr Ile Lys
 290 295 300
 Arg Val Glu Thr Gln Asp Gly Lys Leu Gly Leu Glu Tyr Pro His His
 305 310 315 320
 Asp His Ala His Val Leu Met Leu Ser Asp Ile Glu Ile Gly Lys Asp
 325 330 335
 Ile Pro Asp Pro His Ala Ile Glu His Ala Arg Glu Leu Glu Lys His
 340 345 350

WO 01/14421

Lys Val Gly Met Asp Thr Leu Arg Ala Leu Gly Phe Asp Glu Glu Val
 355 360 365
 Ile Leu Asp Ile Val Arg Thr His Asp Ala Pro Thr Pro Phe Pro Ser
 370 375 380
 Asn Glu Lys Asp Pro Asn Met Met Lys Glu Trp Leu Ala Thr Val Ile
 385 390 395 400
 Lys Leu Asp Leu Gly Ser Arg Lys Asp Pro Leu Gln Arg Lys Gly Leu
 405 410 415
 Ser Leu Leu Pro Asn Leu Glu Thr Leu Gly Ile Gly Phe Thr Pro Ile
 420 425 430
 Lys Asp Ile Ser Pro Val Leu Gln Phe Lys Lys Leu Lys Gln Leu Leu
 435 440 445
 Met Thr Lys Thr Gly Val Thr Asp Tyr Arg Phe Leu Asp Asn Met Pro
 450 455 460
 Gln Leu Glu Gly Ile Asp Ile Ser Gln Asn Asn Leu Lys Asp Ile Ser
 465 470 475 480
 Phe Leu Ser Lys Tyr Lys Asn Leu Thr Leu Val Ala Ala Ala Asp Asn
 485 490 495
 Gly Ile Glu Asp Ile Arg Pro Leu Gly Gln Leu Pro Asn Leu Lys Phe
 500 505 510
 Leu Val Leu Ser Asn Asn Lys Ile Ser Asp Leu Ser Pro Leu Ala Ser
 515 520 525
 Leu His Gln Leu Gln Glu Leu His Ile Asp Asn Asn Gln Ile Thr Asp
 530 535 540
 Leu Ser Pro Val Ser His Lys Glu Ser Leu Thr Val Val Asp Leu Ser
 545 550 555 560
 Arg Asn Ala Asp Val Asp Leu Ala Thr Leu Gln Ala Pro Lys Leu Glu
 565 570 575
 Thr Leu Met Val Asn Asp Thr Lys Val Ser His Leu Asp Phe Leu Lys
 580 585 590
 Asn Asn Pro Asn Leu Ser Ser Leu Ser Ile Asn Arg Ala Gln Leu Gln
 595 600 605
 Ser Leu Glu Gly Ile Glu Ala Ser Ser Val Ile Val Arg Val Glu Ala
 610 615 620
 Glu Gly Asn Gln Ile Lys Ser Leu Val Leu Lys Asp Lys Gln Gly Ser
 625 630 635 640
 Leu Thr Phe Leu Asp Val Thr Gly Asn Gln Leu Thr Ser Leu Glu Gly
 645 650 655
 Val Asn Asn Phe Thr Ala Leu Asp Ile Leu Ser Val Ser Lys Asn Gln

WO 01/14421

660
 Leu Thr Asn Val Asn Leu Ser Lys Pro Asn Lys Thr Val Thr Asn Ile
 675 680 685
 Asp Ile Ser His Asn Asn Ile Ser Leu Ala Asp Leu Lys Leu Asn Glu
 690 695 700
 Gln His Ile Pro Glu Ala Ile Ala Lys Asn Phe Pro Ala Val Tyr Glu
 705 710 715 720
 Gly Ser Met Val Gly Asn Gly Thr Ala Glu Glu Lys Ala Ala Met Ala
 725 730 735
 Thr Lys Ala Lys Glu Ser Ala Gln Glu Ala Ser Glu Ser His Asp Tyr
 740 745 750
 Asn His Asn His Thr Tyr Glu Asp Glu Glu Gly His Ala His Glu His
 755 760 765
 Arg Asp Lys Asp Asp His Asp His Glu His Glu Asp Glu Asn Glu Ala
 770 775 780
 Lys Asp Glu Gln Asn His Ala Asp
 785 790

<210> 5

<211> 2469

<212> DNA

<213> Streptococcus agalactiae

<400> 5

gtgaagaaaa catatgggta tateggctca gttgctgcta ttttactagc tactcatatt 60
 ggaagttacc agcttggtta gcatcatatg ggtctagcaa caaaggacaa tcagattgcc 120
 tatattgatg atagcaaagg taaggtaaaa gcccctaaaa caaacaaaac gatggatcaa 180
 atcagtgtcg aagaaggeat ctctgtctgaa cagatcgtag tcaaaattac tgaccaaggt 240
 tatgttacct cacacgggta ccattatcat tttacaatg ggaaagttcc ttatgatgctg 300
 attattagtg aagagtgtgt gatgacggat cctaattacc attttaaaca atcagacgtt 360
 atcaatgaaa tcttagacgg ttacgttatt aaagtcaatg gcaactatta tgtttacctc 420
 aagccaggta gtaagcgcaa aaacattcga accaaaacaa aaattgctga gcaagtagcc 480
 aaaggaacta aagaagctaa agaaaaaggt ttagctcaag tggcccatct cagtaaagaa 540
 gaagttgcgg cagtcaatga agcaaaaaga caaggacgct atactacaga cgatggctat 600
 atttttagtc cgacagatat cattgatgat ttaggagatg cttatttagt acctcatggt 660
 aatcactatc atttatattcc taaaaaagat ttgtctccaa gtgagctagc tgctgcacaa 720
 gcctactgga gtcaaaaaca aggtcgaggt gctagaccgt ctgattaccg cccgacacca 780
 gccccaggte gtaggaaagc cccaattcct gatgtgacgc ctaaccctgg acaaggtcat 840
 cagccagata acgggtggtta tcatccagcg cctcctaggc caaatgatgc gtcacaaaac 900
 aaacacccaaa gagatgagtt taaaggaaaa acctttaagg aactttttaga tcaactacac 960
 cgtcttgatt tgaaataccg tcatgtggaa gaagatgggt tgatttttga accgactcaa 1020
 gtgatcaaat caaacgcttt tgggtatgtg gtgcctcatg gagatcatta tcatattatc 1080
 ccaagaagtc agttatcacc acttgaaatg gaattagcag atcgatactt agccggccaa 1140
 actgatgaca acgactcagg ttcagatcac tcaaaacat cagataaaga agtgacacat 1200
 acctttcttg gtcatcgcat caaagcttac ggaaaaggct tagatggtta accatatgat 1260
 acgagtgtatg cttatgtttt tagtaaaagaa tccattcatt cagtggataa atcaggagtt 1320
 acagctaaac acggagatca ttccactat ataggatttg gagaacttga acaatatgag 1380
 ttggatgagg tcgctaactg ggtgaaagca aaagggtcaag ctgatgagct tgttgctgct 1440
 ttggatcagg aacaaggcaa agaaaaacca ctctttgaca ctaaaaaagt gagtgcgcaa 1500
 gtaacaaaag atggtaaaagt gggctatatt atgccaaaag atggcaagga ctatttctat 1560

WO 01/14421

gctcggtatc aacttgattt gactcagatt gcttttgcg aacaagaact aatgcttaaa 1620
 gataagaagc attaccgtta tgacattggt gatacaggca ttgagccacg acttgctgta 1680
 gatgtgtcaa gtctgccgat gcatgctggt aatgctactt acgatactgg aagttcgttt 1740
 gttatcccac atattgatca tatecatgtc gttccgtatt catgggtgac gcgcaatcag 1800
 attgcaacaa tcaagtatgt gatgcaacac cccgaagtgc gtccggatgt atgggtctaag 1860
 ccagggcacg aagagtcagg ttcggtcatt ccaaagtgtta cgcctcttga taaacgtgct 1920
 ggtatgccaa actggcaaat tatccattct gctgaagaag ttcaaaaagc cctagcagaa 1980
 ggtcggtttg cagcaccaga cggctatatt ttcgatccac gagatgtttt ggcaaaaagaa 2040
 acttttgtat ggaaagatgg ctcccttagc atcccaagag cagatggcag ttcattgaga 2100
 accattaata aatccgatct atcccaagct gaggggcaac aagctcaaga gttattggca 2160
 aagaaaaatg ctggtgatgc tactgatacg gataaacctg aagaaaaagca acaggcagat 2220
 aagagcaatg aaaaccaaca gccaaagtga gccagtaaag aagaaaaaga atcagatgac 2280
 tttatagaca gtttaccaga ctatggtcta gatagagcaa cctagaaga tcatatcaat 2340
 caattagcac aaaaagctaa tatcgatcct aagtatctca ttttccaacc agaagggtgc 2400
 caattttata ataaaaatgg tgaattggta acttatgata tcaagacact tcaacaaata 2460
 aacccttaa

<210> 6

<211> 822

<212> PRT

<213> Streptococcus agalactiae

<400> 6

Val Lys Lys Thr Tyr Gly Tyr Ile Gly Ser Val Ala Ala Ile Leu Leu
 1 5 10 15

Ala Thr His Ile Gly Ser Tyr Gln Leu Gly Lys His His Met Gly Leu
 20 25 30

Ala Thr Lys Asp Asn Gln Ile Ala Tyr Ile Asp Asp Ser Lys Gly Lys
 35 40 45

Val Lys Ala Pro Lys Thr Asn Lys Thr Met Asp Gln Ile Ser Ala Glu
 50 55 60

Glu Gly Ile Ser Ala Glu Gln Ile Val Val Lys Ile Thr Asp Gln Gly
 65 70 75 80

Tyr Val Thr Ser His Gly Asp His Tyr His Phe Tyr Asn Gly Lys Val
 85 90 95

Pro Tyr Asp Ala Ile Ile Ser Glu Glu Leu Leu Met Thr Asp Pro Asn
 100 105 110

Tyr His Phe Lys Gln Ser Asp Val Ile Asn Glu Ile Leu Asp Gly Tyr
 115 120 125

Val Ile Lys Val Asn Gly Asn Tyr Tyr Val Tyr Leu Lys Pro Gly Ser
 130 135 140

Lys Arg Lys Asn Ile Arg Thr Lys Gln Gln Ile Ala Glu Gln Val Ala
 145 150 155 160

Lys Gly Thr Lys Glu Ala Lys Glu Lys Gly Leu Ala Gln Val Ala His
 165 170 175

Leu Ser Lys Glu Glu Val Ala Ala Val Asn Glu Ala Lys Arg Gln Gly
 180 185 190

WO 01/14421

Arg Tyr Thr Thr Asp Asp Gly Tyr Ile Phe Ser Pro Thr Asp Ile Ile
 195 200 205
 Asp Asp Leu Gly Asp Ala Tyr Leu Val Pro His Gly Asn His Tyr His
 210 215 220
 Tyr Ile Pro Lys Lys Asp Leu Ser Pro Ser Glu Leu Ala Ala Ala Gln
 225 230 235 240
 Ala Tyr Trp Ser Gln Lys Gln Gly Arg Gly Ala Arg Pro Ser Asp Tyr
 245 250 255
 Arg Pro Thr Pro Ala Pro Gly Arg Arg Lys Ala Pro Ile Pro Asp Val
 260 265 270
 Thr Pro Asn Pro Gly Gln Gly His Gln Pro Asp Asn Gly Gly Tyr His
 275 280 285
 Pro Ala Pro Pro Arg Pro Asn Asp Ala Ser Gln Asn Lys His Gln Arg
 290 295 300
 Asp Glu Phe Lys Gly Lys Thr Phe Lys Glu Leu Leu Asp Gln Leu His
 305 310 315 320
 Arg Leu Asp Leu Lys Tyr Arg His Val Glu Glu Asp Gly Leu Ile Phe
 325 330 335
 Glu Pro Thr Gln Val Ile Lys Ser Asn Ala Phe Gly Tyr Val Val Pro
 340 345 350
 His Gly Asp His Tyr His Ile Ile Pro Arg Ser Gln Leu Ser Pro Leu
 355 360 365
 Glu Met Glu Leu Ala Asp Arg Tyr Leu Ala Gly Gln Thr Asp Asp Asn
 370 375 380
 Asp Ser Gly Ser Asp His Ser Lys Pro Ser Asp Lys Glu Val Thr His
 385 390 395 400
 Thr Phe Leu Gly His Arg Ile Lys Ala Tyr Gly Lys Gly Leu Asp Gly
 405 410 415
 Lys Pro Tyr Asp Thr Ser Asp Ala Tyr Val Phe Ser Lys Glu Ser Ile
 420 425 430
 His Ser Val Asp Lys Ser Gly Val Thr Ala Lys His Gly Asp His Phe
 435 440 445
 His Tyr Ile Gly Phe Gly Glu Leu Glu Gln Tyr Glu Leu Asp Glu Val
 450 455 460
 Ala Asn Trp Val Lys Ala Lys Gly Gln Ala Asp Glu Leu Val Ala Ala
 465 470 475 480
 Leu Asp Gln Glu Gln Gly Lys Glu Lys Pro Leu Phe Asp Thr Lys Lys
 485 490 495
 Val Ser Arg Lys Val Thr Lys Asp Gly Lys Val Gly Tyr Ile Met Pro

WO 01/14421

500 505 510
 Lys Asp Gly Lys Asp Tyr Phe Tyr Ala Arg Tyr Gln Leu Asp Leu Thr
 515 520 525
 Gln Ile Ala Phe Ala Glu Gln Glu Leu Met Leu Lys Asp Lys Lys His
 530 535 540
 Tyr Arg Tyr Asp Ile Val Asp Thr Gly Ile Glu Pro Arg Leu Ala Val
 545 550 555 560
 Asp Val Ser Ser Leu Pro Met His Ala Gly Asn Ala Thr Tyr Asp Thr
 565 570 575
 Gly Ser Ser Phe Val Ile Pro His Ile Asp His Ile His Val Val Pro
 580 585 590
 Tyr Ser Trp Leu Thr Arg Asn Gln Ile Ala Thr Ile Lys Tyr Val Met
 595 600 605
 Gln His Pro Glu Val Arg Pro Asp Val Trp Ser Lys Pro Gly His Glu
 610 615 620
 Glu Ser Gly Ser Val Ile Pro Asn Val Thr Pro Leu Asp Lys Arg Ala
 625 630 635 640
 Gly Met Pro Asn Trp Gln Ile Ile His Ser Ala Glu Glu Val Gln Lys
 645 650 655
 Ala Leu Ala Glu Gly Arg Phe Ala Ala Pro Asp Gly Tyr Ile Phe Asp
 660 665 670
 Pro Arg Asp Val Leu Ala Lys Glu Thr Phe Val Trp Lys Asp Gly Ser
 675 680 685
 Phe Ser Ile Pro Arg Ala Asp Gly Ser Ser Leu Arg Thr Ile Asn Lys
 690 695 700
 Ser Asp Leu Ser Gln Ala Glu Trp Gln Gln Ala Gln Glu Leu Leu Ala
 705 710 715 720
 Lys Lys Asn Ala Gly Asp Ala Thr Asp Thr Asp Lys Pro Glu Glu Lys
 725 730 735
 Gln Gln Ala Asp Lys Ser Asn Glu Asn Gln Gln Pro Ser Glu Ala Ser
 740 745 750
 Lys Glu Glu Lys Glu Ser Asp Asp Phe Ile Asp Ser Leu Pro Asp Tyr
 755 760 765
 Gly Leu Asp Arg Ala Thr Leu Glu Asp His Ile Asn Gln Leu Ala Gln
 770 775 780
 Lys Ala Asn Ile Asp Pro Lys Tyr Leu Ile Phe Gln Pro Glu Gly Val
 785 790 795 800
 Gln Phe Tyr Asn Lys Asn Gly Glu Leu Val Thr Tyr Asp Ile Lys Thr
 805 810 815

WO 01/14421

Leu Gln Gln Ile Asn Pro
820

INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/US 00/23417

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/315 C12N15/31 C07K16/12 A61K39/09 A61K39/40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category * Citation of document, with indication, where appropriate, of the relevant passages

Relevant to claim No.

X WO 98 18930 A (HUMAN GENOME SCIENCES INC
;CHOI GIL H (US); HROMOCKYJ ALEX (US); J)
7 May 1998 (1998-05-07)
SEQ ID NO:55
page 59

8,9,
11-24

X

SPELLERBERG B ET AL: "Streptococcus
agalactiae Lmb (lmb) gene, complete
cds;and unknown gene"
EMBL NUCLEOTIDE SEQU,
11 February 1999 (1999-02-11),
XP002125180
cited in the application
the whole document

1-5,7-10

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

9 January 2001

Date of mailing of the international search report

18.01.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Bilang, J

INTERNATIONAL SEARCH REPORT

Intern. Application No

PCT/US 00/23417

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 99 42588 A (BIOCHEM VACCINS INC ; BRODEUR BERNARD R (CA); CHARLEBOIS ISABELLE () 26 August 1999 (1999-08-26) figures 3A, 3C	1-3, 5, 8, 9, 11-24
P,X	WO 00 06736 A (HANNIFFY SEAN BOSCO ; LE PAGE RICHARD WILLIAM FALLA (GB); WELLS JER) 10 February 2000 (2000-02-10) clone 18 figure 1	1-3, 5, 7-9, 11-24

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/23417

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 20-24 are directed to a method of treatment of the human/animal body and/or a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-24, all partially

Polypeptide having SEQ ID NO: 2 and gene encoding the polynucleotide (SEQ ID NO: 1); antibodies specific for said polypeptide; vector and cells comprising said polynucleotide; composition comprising said polypeptide and methods making use of said polypeptide or antibodies.

2. Claims: 1-24, all partially

Polypeptide having SEQ ID NO: 4 and gene encoding the polynucleotide (SEQ ID NO: 3); antibodies specific for said polypeptide; vector and cells comprising said polynucleotide; composition comprising said polypeptide and methods making use of said polypeptide or antibodies.

3. Claims: 1-24, all partially

Polypeptide having SEQ ID NO: 6 and gene encoding the polynucleotide (SEQ ID NO: 5); antibodies specific for said polypeptide; vector and cells comprising said polynucleotide; composition comprising said polypeptide and methods making use of said polypeptide or antibodies.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/23417

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9818930 A	07-05-1998	AU 5194598 A	22-05-1998
		AU 6909098 A	22-05-1998
		EP 0942983 A	22-09-1999
		EP 0941335 A	15-09-1999
		WO 9818931 A	07-05-1998
		US 6159469 A	12-12-2000
WO 9942588 A	26-08-1999	AU 2505999 A	06-09-1999
		EP 1054971 A	29-11-2000
		NO 20004161 A	19-10-2000
WO 0006736 A	10-02-2000	NONE	